Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC

Leukemia. 2023 Oct;37(10):2138-2141. doi: 10.1038/s41375-023-02004-w. Epub 2023 Aug 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Myelodysplastic Syndromes* / diagnosis
  • Myelodysplastic Syndromes* / genetics
  • Prognosis
  • Risk Assessment